Recent Trends in Risk Factors Associated with Kidney Diseases

Okolonkwo Benjamin Nnamdi *

Department of Medical Laboratory Science, Faculty of Allied Health Sciences, Pamo University of Medical Sciences (PUMS), Port Harcourt. Rivers State. Nigeria.

Ajibo Doris Nnenna

Department of Experimental Pharmacology and Toxicology, University of Port Harcourt (UNIPORT), Port Harcourt. Rivers State. Nigeria.

George-Opuda Maureen Ibitroko

Department of Chemical Pathology / Clinical Chemistry, Faculty of Medical Laboratory Sciences, Rivers State University (RUST), Port Harcourt. Rivers State. Nigeria.

Nwahiri Jude Donatus

Department of Chemical Pathology / Clinical Chemistry, Faculty of Medical Laboratory Sciences, Rivers State University (RUST), Port Harcourt. Rivers State. Nigeria.

*Author to whom correspondence should be addressed.


The kidneys play a vital role in our overall health and well-being. Their ability to filter waste, reabsorb essential nutrients and maintain a balance of fluids and electrolytes in our body is essential for our health. However, various factors such as age-related changes, exposure to toxins, and lifestyle habits can contribute to a decline in kidney function, leading to potential health issues. Therefore, it is crucial to identify the risk factors that can cause kidney damage and take early interventive measures to slow down the progression of chronic kidney disease. By raising awareness of these risk factors, we can work towards preventing the development of chronic kidney disease and reducing the incidence of end-stage renal disease. It is important to note that several of these risk factors are modifiable, and early diagnosis and treatment of kidney disease can prevent severe complications. Through regular check-ups, identifying these risk factors through panels of tests, and taking a proactive approach towards our health, we can ensure that we maintain healthy kidney function and prevent potential health problems. In conclusion, by taking a constructive approach towards our health and being aware of the risk factors that can cause kidney damage, we can work towards maintaining healthy kidney function and preventing chronic kidney disease. Let us prioritize our health and make changes to our lifestyle habits to reduce the risk of kidney disease and ensure our long-term well-being.

Keywords: Kidney, toxins, risk factors, age, diabetes, chronic, end-stage

How to Cite

Nnamdi , O. B., Nnenna , A. D., Ibitroko , G.-O. M., & Donatus , N. J. (2024). Recent Trends in Risk Factors Associated with Kidney Diseases . Asian Journal of Research in Nephrology, 7(1), 7–30. Retrieved from


Download data is not yet available.


Lote CJ. Principles of Renal Physiology, 5th Edition. Springer. 2012;21 – 26..

Molina DK, DiMaio VJ. Normal Organ Weights in Man: Part II – The Brain, Lungs, Liver, Spleen and Kidneys. Am. J. Forensic Med. Pathol. 2012;33(4):368–372. Available: PMD: 22182984.

Waugh A, Grant A. Ross and Wilson anatomy and physiology in health and illness. 11th edn. Churchill Livingston, Edinburgh; New York;2010.

Imai E, Horio M, Watanabe T, Iseki K, Yamagata K, Hara S, et al. Prevalence of chronic kidney disease in the Japanese general population. Clinical Exp. Nephrol. 2009;13(6):621–630.

Ellam T, Twohig H, Khwaja A. Chronic kidney disease in elderly people: Disease or disease label? BMJ. 2016;352:h6559.

Tadashi T, Kiyoki K, Megumi O, Shinji K, Akinoni H, Yasunori I, et al. Age differences in the relationships between risk factors and loss of kidney function: A general population cohort study. BMC Nephrology. 2020;21:477–486.

Rasha SS, Mostafa A, Sherouk SE, Ashraf HM, Nagy SA, Mona T. Characteristics, risk factors and outcomes of community-acquired acute kidney injury in the elderly: A prospective tertiary hospital study, Egypt. African Health Sciences. 2022;22(2):350–361.

Epstein M. Aging and the kidney. J. Am. Soc. Nephrol. 1996;7:1106–1122.

Chaudhury D, Raj DSC, Levi M. Effect of Aging on the renal function and disease. In: Brenner & Rector’s. The Kidney, 7th ed. Philadelphia, P. A. Saunders. 2004;2305–2321.

Devaraj M. Chronic Kidney Disease (CKD) in the elderly – A geriatrician’s perspective, The Aging Male. 2007;10:3,113–137.

Munikrishnappa D. Chronic Kidney Disease (CKD) in the elderly – A geriatrician's perspective, The Aging Male, 2007;10(3):113-137. Available:

Davison AM. Renal disease in the elderly. Nephron. 1998;80:6–16.

Godwin M, Moulin B, Etienne J, Fillastre JP. [Renal Aging in Man]. Presse Med. 1992;21:1246–1248.

Hansberry MR, Whittier ML, Krause MW. The elderly patient with chronic kidney disease. Adv. Chronic Kidney Disease. 2005;12:71–77.

Soderland P, Lovekar S, Weiner DE et al. Chronic kidney disease associated with environmental toxins and exposures. Adv. Chronic Kidney Dis. 2010;17:254–264.

Vervaet BA, D’Haese PC, Verhulst A. Environmental toxin-induced acute kidney injury. Clinical Kidney Journal. 2017;10(6):747–758. Available:

Okolonkwo BN, Nwachuku EO, Ene PC, Okeke CU. The preventive effect of vitamin C on the cellular and functional intergrity of kidney cells in rats following repeated exposure to paraquat. Journal of Xenobiotics. 2014;4:3945:29-39. Available:

Okolonkwo BN, Nyenke CU, Ajibo DN, George-Opuda MI, Odiabara KK. Chronic paraquat exposure on kidney and vitamin E and C treatment benefits. Journal of Biomedicine and Biosensors. 2023;3(3):3-10. Available: bb332.

Ajayi KS, Youssef MK, Bharati VM, Kuyilan KS, Sai KR, Vidya NA, et al. Epidemiology and risk factors of chronic kidney diseases in India – Results from the SEEK (Screening and Early Evaluation of Kidney Disease) study, BMC Nephrology. 2013;14:114 – 115.

Chukwuonye IJ, Ogah OS, Anyabolu EN, Ohagwu KA, Nwabuko OC, Onwuchekwa U, et al. Prevalence of chronic kidney disease in Nigeria: Systematic review of population-based studies. International Journal of Nephrology and Renovascular Disease. 2018;11:165–172. Available:

National Institute of Health and Clinical Excellence, NIHCE. Acute kidney Injury: Prevention, Detection and Management; 2013. Available:

Centre for Disease Control and Prevention, CDC&P. Chronic kidney disease in the United States. Atlanta GA: US Department of Health and Human Services;2019. Available:

Martinez K. Everything you need to know about kidney failure. Online Material; 2021. Available:

Rumeyza K. Risk Factors for chronic kidney disease: An update. PMC: Kidney Int. Suppl. 2013;3(4):368–371. Available:

McClellan WM, Flanders WD. Risk Factors for progressive chronic kidney disease. Journal of American Society of Nephrology. 2003;14:S65–S70. Available:

Kottgen A, Glazer NL, Dehghan A, et al. Multiple loci associated with indices of renal function and chronic kidney disease. Nat. Ge net. 2009;41:712–717.

Pollak MR, Genovese G, Friedman DJ. APOL1 and kidney disease. Curr. Opin. Nephrol. Hypertens. 2012;21:179–182.

Su SL, Lu KC, Lin YF, et al. Gene polymorphisms of angiotensin-converting enzyme angiotensin II type 1 receptor among chronic kidney disease patients in a Chinese population. J. Renin Angiotensin Aldosterone System. 2012;13:148–154.

Song EY, McClellan WM, McClellan A, et al. Effects of community characteristics on familial clustering of end-stage renal disease. Am. J. Nephrol. 2009;30:499–504.

Iseki K. Factors influencing the development of end-stage renal disease. Clin. Exp. Nephrol. 2005;9:5–14.

Takamatsu N, Abe H, Tominaga T, Nakahara K, Ito Y, Okumoto Y, et al. Risk factors for chronic kidney disease in Japan: A community-based study. BMC Nephrol. 2009;27(10):34. Available: PMID: 19860890 PMCID: PMC2773767

Lackland DT, Egan BM, Fan JZ, Syddail HE. Low birth weight contributes to the excess prevalence of end-stage renal disease in African americans. The Journal of Clinical Hypertension, 2007;3(1):29-31. Available:

Falodia J, Singla MK. CKD epidemiology and risk factors. Clin. Queries Nephrol. 2012;1:249–252.

Suleymanlar G, Yparmak MR, Seyahi N, et al. Registry of the nephrology dialysis and transplantation in Turkey (Registry - 2011) Istanbul: Published by the Turkish Society of Nephrology;2011.

MacKenzie HS, Lawler EV, Brenner BM. Congenital oligonephropathy: The fetal flaw in essential hypertension, Kidney Int. Suppl. 1996;55:S30–S34.

Luyckx VA, Brenner BM. The clinical importance of nephron mass. J. Am. Soc. Nephrol. 2010;21:898–910.

Vikse BE, Irgens LM, Leivestad T et al. Low birth weight increases risk for end-stage renal disease. J. Am. Soc. Nephrol. 2008;19:151–157.

Chang A, Kramer H. CKD progression: A risky business. Nephrol. Dial. Transplant. 2012;27:2607–2609.

Ejerblad E, Michael FC, Lindblad P, et al. Obesity and risk for chronic renal failure. J. Am. Soc. Nephrol. 2006;17:1695–1702.

Mirrakhimov AE. Obstructive sleep apnea and kidney disease: Is there any direct link. Sleep Breath. 2012;16:1009–1016.

Kwakernaak AJ, Zelle DM, Bakker SJL, et al. Central body fat distribution associates with unfavourable renal hemodynamics independent of body mass index. J. Am. Soc. Nephrol. 2013;24:987–994.

Krop JS, Coresh J, Chambles LE, et al. A community-based study of explanatory factors for the excess risk for early renal function decline in black vs white’s diabetes: The atherosclerosis risk in community study. Arch. Intern. Med. 1999;159:1777–1783.

Bleyer AJ, Shemanski LR, Burke GL, et al. Tobacco, hypertension and vascular disease: Risk factors for renal functional decline in an older population. Kidney Int. 1999;57:2072–2079.

Orth SR, Schroeder T, Ritz E, et al. Effects of smoking on renal function in patients with type 1 and 2 diabetes mellitus. Nephrol. Dial. Transplant. 2005;20:2414–2419.

Perneger TV, Whelton PK, Klag MJ. Risk of kidney failure associated with the use of acetaminophen, aspirin and nonsteroidal anti-inflammatory drugs, N. Eng. J. Med. 1994;25:1675–1679.

Goldstein SL, Devarajan P. Acute kidney injury in childhood: Should we be worried about progression to CKD. Pediatr. Nephrol. 2011;26:509–522.

Collins AJ, Foley RN, Herzog C, Chavers BM, Gildertson D, Isheni A, et al. Excerpts from the US Renal Data System (USRDS) 2009 annual data report. Am J Kidney Disease; 2010:55:S1-S420,(suppl 1). DOI: 10.1053/j.ajkd.2009.10.009

Lea JP, Nicholas SB. Diabetes mellitus and hypertension: Key risk factors for kidney disease. J. Natl. Med. Assoc. 2002;94:7S–15S.

Lu MC, Chen IJ, Hsu LT, Chen YJ, Tsou MT, Tung TH, et al. Metabolic risk factors associated with chronic kidney disease in a middle-aged and elderly Taiwanese population: A cross-sectional study. Frontiers in Medicine. 2021;8:1–8. Available:

Veruoort G, Veldman B, Berden JH, Smits P, Wetzels JF. Glomerular hyperfiltration in type 1 Diabetes mellitus results from primary changes in proximal tubular sodium handling without changes in volume expansion. Eur. J. Clin. Investi. 2005;35:330–336. Available:

Mogensen CE, Christensin CK. Predicting diabetic nephropathy in insulin-dependent patients. N. Engl. J. Med. 1984;311:89–93. Available:

Jin Y, Moriya T, Matsubara M, Fujita Y. Glomerular hyperfiltration in non-proteinuric and non-hypertensive Japanese type 2 diabetic patients. Diabetes Res. Clin. Pract. 2006;71:264–271. Available:

Rudkerg S, Persson B, Dahlquist G. Increased glomerular filtration rate as a predictor of diabetic nephropathy – An 8 – Year perspective study. Kidney Int. 1992;41:822–828. Available:

Song H, Wang X, Cai Q, Ding W, Huang S, Zhuo I. Association of metabolic syndrome with decreased glomerular filtration rate among 15,468 Chinese adults: A cross-sectional study. PLOS one. 2014;9:ell3450. Available:,0113450

Blaslov K, Buhim T, Duvnjak L. Waist-to-height-ratio is independently associated with chronic kidney disease in overweight type 2 diabetic patients. Endocr. Res. 2015;40:194–198. DOI: 10.3109/07435800.2014.987868

Shulman NB, Ford CE, Hall WD, et al. Prognostic value of serum creatinine and effect of treatment of hypertension on renal function: Results from the hypertension detection and follow-up program. The hypertension detection and follow-up program cooperative group. Hypertension. 1989;13:180–193.

Omeire CA, Oparaocha ET, Abanobi OC, Ibe SNO, Nwoke EA. Pattern of distribution of the risk factors of chronic kidney disease among adults in Owerri, Imo-State, Nigeria. European Journal of Public Health Studies. 2019;1(2):64–77.

Inoue T, Iseki K, Iseki C, et al. Heart rate as a risk factor for developing chronic kidney disease: longitudinal analysis of a screened cohort. Clin. Exp. Nephrol. 2009;13:487–493.

Pradeep AR, Kathariya R, Raju A, et al. Risk factors for chronic kidney diseases may include periodontal diseases, as estimated by the correlations of plasma pentaxin–3 levels: A case – control study. Int. Urol. Nephrol. 2012;44:829–839.

Obermayr RP, Temml C, Gutjahr G, et al. Elevated uric acid increases the risk for kidney disease. J. Am. Soc. Nephrol. 2008;19:2407–2413.

Tanaka H, Shiohira Y, Uezu Y, Higa A, Iseki k. Metabolic syndrome and chronic kidney disease in Okinawa, Japan. Kidney Int. 2006;69:369–374. Available:

Iseki K. Metabolic syndrome and chronic kidney disease: A Japanese perspective on a worldwide problem. J. Nephrol. 2008;21:305–312.

Saito T, Mochizuki T, Uchida K, Tsuchiza K, Nitta K. Metabolic syndrome and risk of progression of chronic kidney disease: A single-centre cohort study in Japan. Heart Vessels. 2013;28:323–329.

Boronat M, Bosch E, Lorenzo D, Quevedo V, Lopez-Rois L, Riano M, et al. Prevalence and determinants of the metabolic syndrome among subjects with advanced nondiabetes-related kidney disease in Gran Canaria, Spain. Ren. Fail. 2016;38:198–203. Available:

Zomorrodian D, Khajavi-Rad A, Avan A, Ebrahimi M, Nematy M, Azarpazhooh MR, et al. Metabolic syndrome components as markers to prognosticate the risk of developing chronic kidney disease: Evidence-based study with 6492 individuals. J. Epidemiol. Community Health. 2015;69:594–598. Available:

Tozawa M, Iseki C, Tokashiki K, Chinen S, Kohagura K, Kinjo K, et al. Metabolic syndrome and risk of developing chronic kidney disease in Japanese adults. Hypertens. Res. 2007;30:937-943. Available:

Kurella M, Lo JC, Chertow GM. Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. J. Am. Soc. Nephrol. 2005;16:2134–2140. Available:

Knight EL, Kramer HM, Curhan GC. High-normal blood pressure and microalbuminuria. Am. J. Kidney Dis. 2003;41:588–595. Available:

Eddy AA. Progression in chronic kidney disease. Adv. Chronic Kidney Dis. 2015;12:353–365. Available:

Fielding S. Toxins that con hurt your kidneys (+How to avoid them). Health Central Medical Reviewer; 2020. Available:

Soderland P, Lovekar S, Weiner DE, Brooks DR, Kaufman JS. Chronic kidney disease associated with environmental toxins and exposures. Adv Chronic Kidney Dis. 2010 ;17(3):254-64. PMID: 20439094. Available:

Environmental Defense Fund. PCBs in Fish: “PCBs in Fish and Shellfish.”;2013.

Harvard Health Publishing. PCBs Risks: “Getting your omega-3s vs. avoiding those PCBs.”; 2004.

American Journal of Epidemiology. Kidney Disease Mortality: “Kidney Disease Mortality and Enviornmental Exposer to Mercury.”; 2006.

Kluwe WM, Hook JB. Effects of environmental chemicals on kidney metabolism and function. Kidney International, 1980;18:648-655.

Kataria A, Trasande L, Trachtman H. The effects of environmental chemicals on renal function. Nature Reviews. Nephrology. 2015;11(10):610-615. Available:

US-Environmental Protection Agency (US.EPA). Guidelines for ecological risk assessment. May,14 1998. Federal Register 63(93):26846 – 26924. Available

Woodruff TJ, Zota AR, Schwartz JM. Environmental chemicals in pregnant women in the United States: NHANES 2003–2004. Environ Health Perspect. 2011;119:878–885.

Agency for Toxic Substance & Disease Registry (ATSDR) AfTSaDR. Toxicological profile for arsenic. U.S. Department of health and human services and public health service, Atlanta; 2007. Available (Accessioned 6/10/2015).

Prasad GVR, Rossi NF. Arsenic intoxication associated with tubulointerstitial nephritis. National Kidney Foundation. 1995;26(2):373–376. Available:

Zheng LY, Umans JG, Yeh F, Francesconi KA, Goessler W, Silbergald EK, et al. The association of urine arsenic with prevalent and incident chronic kidney disease: Evidence from the strong heart study. Epidemiology. 2015;26(4):601–612. Available:

Chen W, Liu Q, Wang H, Chen W, Johnson RJ, Dong X, et al. Prevalence and risk factors of chronic kidney disease: A population study in the Tibetan population. Nephrol Dial Transplant. 2011;26:1592–1599.

Hsueh YM, Chung CJ, Shiue HS, et al. Urinary arsenic species and CKD in a Taiwanese population: A case-control study. Am J Kidney Dis. 2009;54:859–70. [PubMed] [Google Scholar].

Huang CY, Chu JS, Pu YS, Yang HY, Wu CC, Chung CJ, Hsueh YM. Effect of urinary total level and estimated glomerular filtration rate on the risk of renal cell carcinoma in a low arsenic exposure area. Journal of Urology. 2011;185(6):2040–2044. Available:

United States department of labor. Battery alternatives: “Cadmium.” 2019

Jarup L, Akesson A. Current status of cadmium as an environmental health problem. Toxicology and Applied Pharmacology. 2009;238(3):201–208. Available:

Richter PA. Tobacco smoke exposure and levels of urinary metals in the U.S. youths and adult population: The National Health and Nutrition Examination Survey (NHANES) 1999 – 2004. International Journal of Environmental Research and Public Health. 2009;6(7):1930–1946. Available:

Roels HA, VanAssche FJ, Oversteyns M, DeGroof M, Lauwerys RR, Lison D. Reversibility of microproteinuria in cadmium workers with incipient tubular dysfunction after reduction of exposure. American Journal of Industrial Medicine. 1997;31(5):645–652. Available:<645::AID-AJIM21>3.0.CO;2-Y

Li Q, Nishijo M, Nakagawa H, Morikawa Y, Sakurai M, Nekamura K. Relationship between urinary cadmium and mortality in inhabitants of a cadmium-polluted area: A 22-year follow-up study in Japan. Chinese Medical Journal. 2011;124(21):3504–3509. Available:

Akesson A, Lundh T, Vahter M, Bjellerup P, Lidfeldt J, Nerbrand C, et al. Tubular and glomerular kidney effects in swedish women with low environmental cadmium exposure. Environmental Health Perspectives. 2005;113(11): 1627 – 1631. Available:

Hellstrom L, Elinder CG, Dahlberg B, et al. Cadmium exposure and end-stage renal disease. National Kidney Foundation. 2001;38(5):1001–1008.

Mayo Clinic. Lead Poisoning: “Lead Poisoning.”; 2019. Available:

Goyer RA. Mechanism of lead and cadmium nephrotoxicity. Toxicology Letters. 1989;46(1-3):153–162. Available:

Hu H, Rabinowity M, Smith D. Bone lead as a biological marker in epidemiologic studies of chronic toxicity: Conceptual paradigms. Environmental Health Perspectives. 1998;106(1):1–8. Available:

Rosen JF, Chesney RW, Hamstra A, DeLuca HF, Mahaffe KR. Reduction in 1,25 – Dihydroxyvitamin D in children with increased lead absorption. The New England Journal of Medicine. 1980;302:1128–1131. Available:

Chisolm JJ. Jr. The road to primary prevention of lead toxicity in children. Pediatrics. 2001;107:581–583. [PubMed] [Google Scholar] [Ref list].

Khalil-Manesh F, Gonick HC, Cohen A, Bergamaschi E, Matti A. Experimental model of lead nephrothy: II. Effect of removal from lead exposure and chelation treatment with dumercaptosuccinic acid (DMSA). Environmental Research. 1992;58(1-2):35–54. Available:

Ekong EB, Jaar BG, Weaver VM. Lead-related nephrotoxicity: A review of the epidemiologic evidence. Kidney International. 2006;70(12):2074–2084. Available:

Longhman-Adham M. Renal effects of environmental and occupational Lead exposure. Environmental Health Perspectives. 1997;105(9):928–939. Available:

Morgan JM, Hartley MW, Miller RE. Nephropathy in chronic lead poisoning. JAMA Internal Medicine. 1966;118(1):17–29. Available:

Aviv A, John E, Bernstein J, Goldsmith DI, Spitzer A. Lead intoxication during development: Its late effects on kidney function and blood pressure. Kidney International. 1980;17:430 – 437.

Nowack R, Wiecek A Ritz E. Lead and Hypertension: In. contribution to nephrology. The kidney today. By G.M. Berlyne. S. Karger AG. 1992;100:25–34. Available:

Muntner P, He J, Vupputuri S, Coresh J, Batuman V. Blood Lead and chronic kidney disease in the general United States population: results from NHANES III. Kidney Int. 2003;63:1044–1050. [PubMed] [Google Scholar] [Ref list].

Payton M, Hu H, Sparrow D, Young JB, Landsberg L, Weiss ST. Relation between blood lead and urinary biogenic amines in community-exposed men. Am J Epidemiol. 1993;138:815–825. [PubMed] [Google Scholar].

Staessen JA, Lauwerys RR, Buchet JP, Bulpitt CJ, Rondia D, Vanrenterghem Y, Amery A. Impairment of renal function with increasing blood lead concentrations in the general population. The cadmibel study group. N Engl J Med. 1992;327:151–156. [PubMed] [Google Scholar] [Ref list].

Menke A, Muntner P, Batuman V, Silbergeld EK, Guallar E. Blood lead below 0.48 micromol/L (10 microg/dL) and mortality among US adults. Circulation. 2006;114:1388–1394. [PubMed] [Google Scholar].

Yu CC, Lin JL, Lin-Tan DT. Environmental exposure to lead and progression of chronic renal diseases: a four-year prospective longitudinal study. J Am Soc Nephrol. 2004;15:1016–1022. [PubMed] [Google Scholar].

Lin-Tan DT, Lin JL, Yen TH, Chen KH, Huang YL. Long-term outcome of repeated lead chelation therapy in progressive non-diabetic chronic kidney diseases. Nephrology Dialysis Transplantation. 2007;22(10):2924–2931. [PubMed] [Google Scholar].

Lin JL, Lin-Tan DT, Yu CC, Li YJ, Huang YY, Li KL. Environmental exposure to lead and progressive diabetic nephropathy in patients with type II diabetes. Kidney Int. 2006;69:2049–2056. [PubMed] [Google Scholar].

Weaver VM, Fadrowski JJ, Jaar BG. Does calcium disodium EDTA slow CKD progression? Am J Kidney Dis.2012;60:503–506. [PubMed] [Google Scholar].

Landrigan PJ, Etzel RA. Textbook of children’s environmental health. Oxford University Press; Oxford; 2014. [Google Scholar].

Hua J, Pelletier L, Berlin M, Druet P. Autoimmune glomerulonephritis induced by mercury vapour exposure in the Brown Norway rat. Toxicology. 1993;79:119–129. [PubMed] [Google Scholar].

Li SJ, Zhang SH, Chen HP, Zeng CH, Zheng CX, Li LS, Liu ZH. Mercury-induced membranous nephropathy: Clinical and pathological features. Clin J Am Soc Nephrol. 2010;5:439–444. [PMC free article] [PubMed] [Google Scholar].

Arzuaga X, Rieth SH, Bathija A, Cooper GS. Renal effects of exposure to natural and depleted uranium: A review of the epidemiologic and experimental data. J Toxicol Environ Health B Crit Rev. 2010;13:527–545. [PubMed] [Google Scholar].

Homma-Takeda S, Kitahara K, Suzuki K, Blyth BJ, Suya N, Konishi T, Terada Y, Shimada Y. Cellular localization of uranium in the renal proximal tubules during acute renal uranium toxicity. J Appl Toxicol. 2015. Available: [PubMed] [CrossRef] [Google Scholar].

Shelley R, Kim NS, Parsons PJ, Lee BK, Agnew J, Jaar BG, et al. Uranium associations with kidney outcomes vary by urine concentration adjustment method. J Expo Sci Environ Epidemiol. 2014;24:58–64. [PMC free article] [PubMed] [Google Scholar].

McDiarmid MA, Engelhardt SM, Dorsey CD, Oliver M, Gucer P, Wilson PD, et al. Surveillance results of depleted uranium-exposed Gulf War I veterans: Sixteen years of follow-up. J Toxicol Environ Health A. 2009;72:14–29. [PubMed] [Google Scholar].

Magdo HS, Forman J, Graber N, Newman B, Klein K, Satlin L, Amler RW, Winston JA, Landrigan PJ. Grand rounds: Nephrotoxicity in a young child exposed to uranium from contaminated well water. Environ Health Perspect. 2007;115:1237–1241. [PMC free article] [PubMed] [Google Scholar].

Arlt VM, Stiborova M, Schmeiser HH. Aristolochic acid as a probable human cancer hazard in herbal remedies: A review. Mutagenesis. 2002;17:265–277. [PubMed] [Google Scholar].

Hong YT, Fu LS, Chung LH, Hung SC, Huang YT, Chi CS. Fanconi’s syndrome, interstitial fibrosis and renal failure by aristolochic acid in Chinese herbs. Pediatr Nephrol.2006;21:577-579.

DeBroe ME. Chinese herbs nephropathy and balkan endemic nephropathy: Toward a single entity, aristolochic acid nephropathy. Kidney Int. 2012;81:513–515. [PubMed] [Google Scholar].

United States Food and Drug Administration (FDA). Aristolochic acid: FDA warns consumers to discontinue use of botanical products that contain aristolochic acid. Consumer Advisory, FDA; Washington DC; 2015. Available: [Google Scholar]

Gokmen MR, Cosyns JP, Arlt VM, Stiborova M, Phillips DH, Schmeiser HH, Simmonds MS, Cook HT, Vanherweghem JL, Nortier JL, Lord GM. The epidemiology, diagnosis, and management of aristolochic acid nephropathy: A narrative review. Ann Intern Med. 2013 ;158:469–477. [PubMed] [Google Scholar].

Bennett JW, Klich M. Mycotoxins. Clin Microbiol Rev. 2003;16:497–516. [PMC free article] [PubMed] [Google Scholar].

Berndt WO. The role of transport in chemical nephrotoxicity. Toxicol Pathol. 1998 ;26:52–57. [PubMed] [Google Scholar].

Dalal RP, Goldfarb DS. Melamine-related kidney stones and renal toxicity. Nat Rev Nephrol. 2011;7:267–274.

Gossner CM, Schlundt J, Ben-Embarek P, Hird S, Lo-Fo-Wong D, Beltran JJ. The melamine incident: Implications for international food and feed safety. Environ Health Perspect. 2009;117:1803–1808.

Hau AK, Kwan TH, Li PK. Melamine toxicity and the kidney. J Am Soc Nephrol. 2009;20:245–250.

Weidemann DK, Weaver VM, Fadrowski JJ. Toxic environmental exposures and kidney health in children. Paediatric Nephrology. 2016;31(11):2043–2054. Available:

Sabolic I. Common mechanisms in nephropathy induced by toxic metal. Nephrology. 2006;104(3):107–114. Available:

Correa-Rotter R, Wesseling C, Johnson RJ. CKD of unknown origin in Central America: The case for a Mesoamerican nephropathy. Am J Kidney Dis. 2014; 63:506–520.

Wijkstrom J, Leiva R, Elinder CG, Leiva S, Trujillo Z, Trujillo L, Soderberg M, Hultenby K, Wernerson A. Clinical and pathological characterization of Mesoamerican nephropathy: A new kidney disease in Central America. Am J Kidney Dis. 2013;62:908–918.

Weiner DE, McClean MD, Kaufman JS, Brooks DR. The Central American epidemic of CKD. Clin J Am Soc Nephrol. 2013;8:504–511.

Jayasekara JM, Dissanayake DM, Adhikari SB, Bandara P. Geographical distribution of chronic kidney disease of unknown origin in North Central Region of Sri Lanka. Ceylon Med J. 2013;58:6–10.

Weidermann D, Kuo CC, Navas-Acien A, Abraham AG, Weaver V, Fadrowski J, Association of arsenic with kidney function in adolescents and young adults: Results from the national health and nutrition examination survey 2009 – 2012. Environmental Research. 2015;140:317–324. Available:

Weaver VM, Vargas GG, Silbergeld EK, Rothenberg SJ, Fadrowski JJ, Rubio-Andrade M, Parsons PJ, Steuerwald AJ, Navas-Acien A, Guallar E. Impact of urine concentration adjustment method on associations between urine metals and Estimated Glomerular Filtration Rates (eGFR) in adolescents. Environ Res. 2014;132:226–232.

Shelley R, Kim NS, Parsons P, Lee BK, Jaar B, Fadrowski J, et al. Associations of multiple metals with kidney outcomes in lead workers. Occup Environ Med. 2012;69:727–735.

Weaver VM, Kotchmar DJ, Fadrowski JJ, Silbergeld EK. Challenges for environmental epidemiology research: Are bio-marker concentrations altered by kidney function or urine concentration adjustment? J Expos Sci Environ Epidemiol; 2015. Available:

Weidemann DK, Weaver VM, Fadrowski JJ. Toxic environmental exposures and kidney health in children. Pediatric Nephrology. 2016;31:2043-54.